The German skin and personal care multinational already held a minority stake in S-Biomedic.
S-Biomedic will continue to be managed as a standalone entity under Beiersdorf’s existing microbiome program and will complement Beiersdorf's own research activities in this field.
Founded by Veronika Oudova and Bernhard Pätzold, S-Biomedic is active in the research, development and marketing of a method to change the human skin microbiome. The method can be used as an advanced cosmetic or dermatology product for acne recovery, skin aging, or to treat skin diseases and to enhance skin health and beauty.
'It was a pleasure advising Veronika Oudova, Bernhard Pätzold and the other selling shareholders on the sale of a majority stake in S-Biomedic. Congratulations to all parties involved in this transaction, which will boost the further development and commercialisation of S-Biomedic's dermatology products applying their skin microbiome innovations', says partner Philippe Remels, who led the NautaDutilh transaction team which also included Guillaume Milde, Grace Nonneman and Lauren De Brauwer (Corporate M&A).